Diagenode

News

With RNAi across the hemophilia
October 23, 2015

RNA interference (RNAi) may be used as a therapeutic for the bleeding disorder hemophilia. Specifically, artificially-generated, epigenetically-activated RNA molecules such as microRNAs can be used to inhibit gene expression through post-translational gene silencing. Researchers from France and the USA recently treated hemophiliac mice and macaques with a successful RNAi compound (ALN-AT3), which supresses the production of the anti-clotting substance antithrombin. Currently this therapeutic is being investigated in phase 1 clinical trials in individuals with hemophilia A or B.

Source: http://www.newsletter-epigenetik.de/

Read more

Events

  • Symposium: "Signaling through Chromatin"
    Grenoble, France
    Oct 2-Oct 4, 2023
  • EMBL Symposium: The non-coding genome
    Heidelberg, Germany
    Oct 11-Oct 14, 2023
  • IUBMB
    Crete, Greece
    Oct 15-Oct 20, 2023
 See all events

News

 See all news


The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.


       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics